Schizophrenia and Schizoaffective Disorders

Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.

Page 10

Recently published articles about Schizophrenia/Schizoaffective Disorders

PCC
Suicidal Behavior in First-Episode Schizophrenia
Original Research

June 20, 2023

Suicidal behavior is most prevalent in the early phases of illness in first-episode schizophrenia, particularly during hospital admission.
, ,
PCC
Treatment Decision-Making Capacity With the MacCAT-T in Schizophrenia
Brief Report

June 1, 2023

This report is a narrative review of the studies on schizophrenia that evaluated both decision-making capacity for treatment with the MacCAT-T and severity of symptoms using a clinical rating...
JCP
Clinical Follow-Up and Widening LAI Intervals
Commentary

May 31, 2023

Although the administration intervals of long-acting injectable antipsychotics are a starting point for scheduling follow-ups, frequency of prescriber contact should be based on individual risk factors and real-world constraints.
, ,
EMERGENT Trial Data For KarXT Shows Promise in Schizophrenia
news

May 30, 2023

KarXT shows potential in alleviating schizophrenia symptoms while effectively managing side effects, offering hope for improved outcomes.
The Advantages of Long-Acting Injectables in Early-Phase Schizophrenia
news

May 8, 2023

Long-acting injectables, when used as a first-line treatment in early-phase schizophrenia, may reduce relapses.
Slow-Release UZEDY Gains FDA Approval, Reduces Schizophrenia Relapse by 80%
news

May 2, 2023

In a Phase 3 clinical trial, UZEDY demonstrated up to 80 percent reduction in risk of schizophrenia relapse versus placebo.
JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
, , , et al
Dodgers Highlight Mental Health Expense in Support for Player With Schizophrenia
news

April 18, 2023

The Los Angeles Dodgers re-sign Andrew Toles, who was diagnosed with schizophrenia and bipolar disorder, so he can keep his health coverage.
PCC
Olanzapine and Weight Loss in Early-Onset Schizophrenia
Case Report

April 6, 2023

This is the case of a 15-year-old patient with early-onset schizophrenia maintained on olanzapine who experienced significant weight loss.
, , , et al
JCP
Generalizability of RCTs in First-Episode Schizophrenia
Original Research

March 29, 2023

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting them does not affect key outcome measures but excludes many potential subjects.
, , , et al
Schizophrenia Risk in Diverse Populations Linked to Newly Discovered Genes
news

March 14, 2023

Two genes associated with schizophrenia risk, and a third gene involved in autism, in diverse populations were identified in a new study.
JCP
NNT, NNH, and LHH for Lumateperone
Original Research

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe